Vigil Neuroscience Completes $90 Million Series B Financing To Advance A Pipeline Of Microglia-Targeted Medicines To Treat Rare And Common Neurodegenerative Diseases
Amount Raised
$90 Million
Round Type
Series B
CambridgeOtherBiotechnologyHealthcareDescription
Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the completion of a $90 million Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration. The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.
Quick answer
Vigil Neuroscience raised $90 Million in a Series B round, dated August 18, 2021. Vigil Neuroscience is based in Cambridge, Massachusetts, United States.
- How much did Vigil Neuroscience raise?
- Vigil Neuroscience raised $90 Million in a Series B round on August 18, 2021.
- What does Vigil Neuroscience do?
- Vigil Neuroscience is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system.
- Where is Vigil Neuroscience based and how big is it?
- Vigil Neuroscience is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at Vigil Neuroscience?
- Fundz holds 1 contact at Vigil Neuroscience. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Biotechnology around the same time
Companies in the same sectors as Vigil Neuroscience that raised within 45 days of this round, from Fundz verified event records.
- Expansion Therapeutics raised $80M (Series B) on September 29, 2021.
- TriSalus Life Sciences raised $24M on September 29, 2021.
- Cingulate raised an undisclosed amount on September 28, 2021.
- Athos Therapeutics, Inc. raised $13M on September 28, 2021.
- Journey Medical Corporation raised $19M on September 22, 2021.
- Triana Biomedicines raised $10M on September 17, 2021.
Who to call at Vigil Neuroscience, and when
A new round usually means Vigil Neuroscience is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Vigil Neuroscience raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Vigil Neuroscience, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Vigil Neuroscience. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Vigil Neuroscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansVigil Neuroscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.